It’s been a roller-coaster year for those hoping for new drugs to treat Alzheimer’s disease, a leading cause of death with rising treatment costs and no clear answer yet as to its cause.
Clearing proteins, such as amyloid and tau, was... Read more »
Professor of Systems Biology, Columbia University
Director, Life Sciences Institute, University of Michigan
Chief Strategy and Innovation Officer, Blue Cross and Blue Shield of North Carolina
Vice President for Research at UT Health Science Center at San Antonio
Bristol-Myers Squibb this week completed its acquisition of Celgene, a $74 billion deal that creates a pharmaceutical juggernaut. And all it took was the largest asset sale ever required by federal antitrust regulators.
As the Federal Trade Commission reviewed Bristol’s (NYSE:... Read more »
Drug pricing debates and uncertainty associated with Brexit are the issues most likely to keep biopharmaceutical executives awake at night. Nevertheless, senior figures remain optimistic about the industry’s prospects in 2020. These are among the major findings of a survey of... Read more »
When Mark Bakken formed the healthcare technology investment firm HealthX Ventures nearly five years ago, he says hospitals, insurers, and other potential buyers of digital health products were less open to conversations with the kinds of early-stage healthtech startups Bakken’s... Read more »
AstraZeneca says it will establish centers for drug research and artificial intelligence development in China. The pharmaceutical giant has also set up a $1 billion fund to foster biotech innovation in that country.
The doors have opened at a GE Healthcare-supported open-access lab for startups at AstraZeneca’s former global center for oncology research and development at Alderley Park, the largest bioscience research campus in the UK.
Nuance Communications’ plan to lighten the clerical burden on physicians is coming into focus, and it involves an assist from tech giant Microsoft.
Five years ago, the big tech incubator Y Combinator started to welcome life sciences companies into its sizable startup classes, which had previously nurtured entrepreneurs in information technology almost exclusively.
That opening to biotech startups in 2014 was controversial at the... Read more »
Exact Sciences has taken another step toward ramping up sales of its flagship product, a non-invasive, stool-based screening test for colorectal cancer. The FDA has approved the test, Cologuard, for eligible, average-risk patients ages 45 and older, which expands the... Read more »
It’s time to catch up on recent news in Wisconsin’s innovation community. Read on for details.
Principal of Capital Midwest Fund
President and founder of Wantable
President and CEO of BrightStar Wisconsin Foundation
Software Engineer at Skelmir
Director, Genome Center, University of Wisconsin-Madison; Principal Investigator, Lloyd Smith Research Group, University of Wisconsin-Madison; Chemistry Professor, University of Wisconsin-Madison
President, Marquette University
Founder and CEO of Propagate Health
Co-founder of Cellular Dynamics International
Founder & CEO of Forward Health Group